Combination Of Doravirine/Islatravir Effective For Maintaining HIV Virologic Suppression In Adult Patients, Study Finds

Infectious Disease Advisor (3/12, Nye) reports study results indicate that “the dual therapy combination of doravirine (DOR) plus islatravir (ISL)” administered daily “via a single-tablet regimen” is “noninferior to bictegravir (BIC) plus emtricitabine (FTC) and tenofovir alafenamide (TAF) for maintaining HIV virologic suppression in adult patients.” Researchers found that “at week 48, most patients across the DOR/ISL and BIC/FTC/TAF groups (91.5% and 94.2%, respectively) exhibited HIV virologic suppression.” They concluded, “DOR/ISL was well tolerated with a similar safety profile to BIC/FTC/TAF and did not adversely affect lymphocytes.” The study was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2025.